文献速递关节外科

阿司匹林在低危无菌翻修全膝关节置换术中预防静脉血栓栓塞安全有效:来自国家队列的证据

Aspirin prophylaxis is safe and effective for venous thromboembolism prophylaxis in low-risk patients undergoing aseptic revision total knee arthroplasty : evidence from a national cohort.
PubMed 文献 · Bone Joint J · 2026-04-01

本研究基于国家数据库,纳入2016年1月1日至2023年4月30日因无菌翻修全膝关节置换术(rTKA)的患者,排除感染、骨折、既往VTE、凝血病或术前抗凝使用者,比较阿司匹林单药与非阿司匹林抗凝的VTE和输血率。倾向性评分1:1匹配后每组4585例,阿司匹林组90天DVT、PE、VTE及30/90天输血率均更低,结论为阿司匹林是安全有效且非劣的VTE预防选择。

要点

  • 无菌rTKA低危患者中,阿司匹林组90天DVT、PE、VTE率均低于非阿司匹林抗凝组。
  • 阿司匹林组30天和90天输血率均更低,出血风险更小。
  • 非阿司匹林组30天内DVT超声使用率更高,可能部分解释VTE检出率更高。

核心结论

  • 在适当选择的低危无菌翻修全膝关节置换术患者中,阿司匹林是安全、有效且非劣的VTE预防选择。

研究设计与样本

  • 基于国家数据库的回顾性队列研究,纳入2016年1月1日至2023年4月30日无菌rTKA患者。
  • 排除感染、骨折、既往VTE、凝血病或术前抗凝使用者,按术后预防分为阿司匹林单药组与非阿司匹林抗凝组。
  • 采用倾向性评分1:1匹配,匹配变量包括人口学、保险、合并症、术后家庭健康使用、住院≤1天、手术年份和CPT代码,每组4585例。

主要发现

  • 匹配队列中,阿司匹林组90天DVT为0.8%(n=38) vs 非阿司匹林组2.1%(n=96),差异有统计学意义(p<0.001)。
  • 阿司匹林组90天PE为0.6%(n=26) vs 2.2%(n=102),VTE为1.1%(n=51) vs 3.3%(n=152),均p<0.001。
  • 阿司匹林组30天输血率为0.6%(n=28) vs 1.2%(n=56),p=0.003;90天输血率为0.7%(n=33) vs 1.4%(n=65),p=0.002。
  • 非阿司匹林组30天内DVT超声使用率7.1%(n=326)高于阿司匹林组5.1%(n=235),p<0.001。
  • 控制CPT代码的回归分析证实阿司匹林与VTE odds降低相关。

临床怎么用

  • 对于无感染、骨折、既往VTE、凝血病或术前抗凝使用的低危无菌rTKA患者,可考虑使用阿司匹林进行VTE预防。
  • 选择阿司匹林时需结合患者个体情况,权衡VTE与出血风险。

局限性

  • 非阿司匹林组DVT超声使用率更高,可能部分导致VTE检出率差异。
  • 研究为回顾性数据库分析,可能存在未测量混杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: While aspirin has been widely adopted as an effective method for deep vein thrombosis (DVT) prevention following primary total knee arthroplasty (TKA), concerns remain with regard to its efficacy in the setting of revision TKA (rTKA). However, the risk for thromboembolic events must be weighed against the increased potential for bleeding with more potent anticoagulants. This study aimed to compare venous thromboembolism (VTE) and transfusion rates between patients receiving aspirin with non-aspirin anticoagulation following aseptic rTKA. METHODS: We identified patients undergoing aseptic rTKA from 1 January 2016 to 30 April 2023 in a national database. Those with infection, fracture, prior VTE, coagulopathy, or preoperative anticoagulant use were excluded. Patients were grouped by postoperative prophylaxis: aspirin alone or non-aspirin anticoagulants. Patients were allocated to one of two categorical treatment groups. Crossover between groups was permitted where clinically indicated. Propensity score matching (1:1) was performed on demographic details, insurance, comorbidities, postoperative home health use, hospital length of stay ≤ one day, surgery year, and Current Procedural Terminology (CPT) code, yielding 4,585 patients per group. Outcomes included 30- and 90-day DVT, pulmonary embolism (PE), overall VTE, and transfusion. RESULTS: In the matched cohort, aspirin use was associated with lower 90-day DVT (0.8% (n = 38) vs 2.1% (n = 96)), PE (0.6% (n = 26) vs 2.2% (n = 102)), and VTE (1.1% (n = 51) vs 3.3% (n = 152); all p < 0.001). Transfusion was also lower in the aspirin group at 30 days (0.6% (n = 28) vs 1.2% (n = 56); p = 0.003) and 90 days (0.7% (n = 33) vs 1.4% (n = 65); p = 0.002). DVT ultrasound use within 30 days was significantly higher in the non-aspirin group (7.1%; n = 326) compared with aspirin (5.1%; n = 235); p < 0.001), which may partly account for the higher VTE detection. Regression controlling for CPT code confirmed reduced odds of VTE with aspirin. CONCLUSION: Aspirin is a safe, effective, and noninferior option for VTE prophylaxis following aseptic rTKA in appropriately selected patients.

来源:Bone Joint J,查看原文。版权归原作者所有。

引用

  1. Kim BI, Chalmers BP, Cushner FD, et al. Aspirin prophylaxis is safe and effective for venous thromboembolism prophylaxis in low-risk patients undergoing aseptic revision total knee arthroplasty : evidence from a national cohort. Bone Joint J. 2026. PMID: 41916535. doi:10.1302/0301-620X.108B4.BJJ-2025-1111.R1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。